Ginkgo Bioworks Holdings Inc. Class A Common Stock (DNA)

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence mode…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

485

Website

investors.ginkgobioworks.com/

Fundamentals

1-day range

$7.5$8.37

Market cap

$528.15M

P/E (trailing)

—

P/E (forward)

-2.48

EPS (trailing)

$-5.35

Dividend yield

—

Beta

1.89

Avg. volume

1.14M

Forecasts

2 analyst ratings

Ginkgo Bioworks Holdings Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $528.15MP/E —
  $5.37$17.58
• AUTL

  Autolus Therapeutics plc American Depositary Share

  $2.34

  ▼ 1.06%
  Market cap $532.31MP/E —
  $1.18$2.58
• PRME

  Prime Medicine Inc. Common Stock

  $3.62

  ▼ 0.69%
  Market cap $532.82MP/E —
  $2.67$6.94
• ZURA

  Zura Bio Limited Class A Ordinary Shares

  $5.73

  ▼ 2.05%
  Market cap $542.44MP/E —
  $1.88$7.44
• FDMT

  4D Molecular Therapeutics Inc. Common Stock

  $14.65

  ▼ 1.74%
  Market cap $551.51MP/E —
  $5.97$16.93
• PROK

  ProKidney Corp. Class A Ordinary Shares

  $1.84

  ▲ 1.10%
  Market cap $495.38MP/E —
  $1.3$3.48
• VALN

  Valneva SE American Depositary Shares

  $6.43

  ▼ 2.13%
  Market cap $491.51MP/E —
  $2.03$5.34

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
  Benzinga · 8/19/2026
• TD Cowen Downgrades Ginkgo Bioworks Holdings (DNA)
  Fintel · 8/8/2026
• TD Cowen Downgrades Ginkgo Bioworks Holdings to Hold, Lowers Price Target to $9
  Benzinga · 8/7/2026
• Ginkgo Bioworks Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/6/2026
• Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/6/2026

• Coen Steven P. · August 24, 2026 · Sale

  330 @ $6.98
• Coen Steven P. · August 21, 2026 · Option Exercise

  156
• Coen Steven P. · August 21, 2026 · Option Exercise

  587
• Canton Barry · July 28, 2026 · Grant

  127.4K
• Canton Barry · July 28, 2026 · Grant

  39.0K
• Canton Barry · July 28, 2026 · Grant

  117.1K
• Canton Barry · July 28, 2026 · Grant

  35.7K
• Shetty Reshma P. · July 28, 2026 · Grant

  117.1K
• Shetty Reshma P. · July 28, 2026 · Grant

  35.7K
• Shetty Reshma P. · July 28, 2026 · Grant

  127.4K
• Shetty Reshma P. · July 28, 2026 · Grant

  39.0K
• Kelly Jason R · July 28, 2026 · Grant

  309.5K
• Kelly Jason R · July 28, 2026 · Grant

  74.3K
• Coen Steven P. · July 17, 2026 · Sale

  752 @ $7.9
• Coen Steven P. · July 16, 2026 · Option Exercise

  312

Institutional Ownership

March 31, 2026

Total shares held

30.70M

Total value held

$185.43M

Institutional holders

165